D LaPorte

Subanesthetic doses of ketamine stimulate psychosis in schizophrenia.

Neuropsychopharmacology August 1, 1995 Adrienne C. Lahti, B Koffel, D LaPorte et al.

We administered ketamine to schizophrenic individuals in a double-blind, placebo-controlled design using a range of subanesthetic doses (0.1, 0.3, and 0.5 mg/kg) to evaluate the nature, dose characteristics, time course, and neuroleptic modulation of N-methyl-D-aspartate (NMDA) antagonist action on mental status in schizophrenia. Ketamine induced a dose-related, short (< 30 minutes) worsening...